The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...

Regeneron, meanwhile, also has designs on the category with its CD20xCD3 bispecific odronextamab, which began a priority review at the FDA last October as a third-line treatment for DLBCL and for ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden ...